Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Fatigue 7Neoplasms 4Brain Neoplasms 3Depression 2Asthenia 2Recurrence 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Meningioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 5Leucovorin 4Irinotecan 4Fluorouracil 4Oxaliplatin 3Capecitabine 3Drug Therapy 2trifluridine tipiracil drug combination 1romiplostim 1napabucasin 1entecavir 1encorafenib 1durvalumab 1apatinib 1abelacimab 1Sunitinib 1Specimen Handling 1Sodium Chloride 1S-1 plus cisplatin 1Radiosurgery 1Palonosetron 1Oviposition 1Nutrition Assessment 1Nucleotides 1Methylphenidate 1Memantine 1Melatonin 1Magnetic Resonance Spectroscopy 1MAA868 1Levoleucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Neoplasms × Methylphenidate × Clear all
NCT00516269 2018-01-03

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
42 enrolled 8 charts
BreastGastrointestinal

Breast Neoplasms, Fatigue, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡